LJLyn H. Jones

Lyn H. Jones

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lyn H. Jones has a total of 647 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Covalent remodeling of CRBN creates a non-canonical neosubstrate interface with NTAQ1

    by Andres H. de la Peña, Justin T. Cruite, Jianwei Che, Mary E. Matyskiela, Philip P. Chamberlain, Eric S. Fischer, Lyn H. Jones

  • Lysine-Targeted Covalent Inhibition of eIF4E with an Anionic Electrophile Warhead

    by Paramita Pal, Erika M. James, Caitlyn E. Given, Hong Yue, Rebecca J. Metivier, Jianwei Che, Eric S. Fischer, Lyn H. Jones

    Covalent strategies offer a powerful route to expand the druggable proteome, yet selective lysine targeting remains difficult due to the high pKa and protonation of the amine side chain. The translation initiation factor eIF4E, an mRNA cap-binding protein that controls nuclear export and translation of oncogenic transcripts, has long been considered an undruggable RNA-binding protein. We apply an anionic electrophile strategy that converts a carboxylic acid within a reversible eIF4E ligand into a vinyl acylsulfonamide warhead, preserving salt-bridge and hydrogen bonding interactions in the cap-binding pocket and facilitating Lys162 deprotonation to enable site-specific engagement. This single-step transformation yields JL-03, a potent covalent eIF4E inhibitor with excellent stability toward biological nucleophiles, consistent with context-dependent activation of the warhead in the binding site. In cells, JL-03 achieves robust target engagement and suppresses translation of the oncogenic driver cyclin D. JL-03 reduces the viability of HOXA9-high acute myeloid leukemia cells with greater potency than reversible eIF4E inhibitors and synergizes with the menin inhibitor revumenib, demonstrating that coordinated transcriptional and translational blockade exhausts leukemic dependencies. These findings establish eIF4E as a tractable covalent target and highlight anionic electrophile installation as a generalizable strategy for lysine-directed covalent inhibitor design.

  • Intrinsic Reactivity of Sulfonyl Imidazole and Triazole Electrophiles for Covalent Probe Design

    by Paramita Pal, Hannah Unsworth, Lyn H. Jones

    Sulfonyl exchange electrophiles are increasingly used in covalent probe and drug discovery, yet their intrinsic reactivity and plasma stability remain poorly defined, limiting rational warhead selection. Here we establish a systematic LC‐MS framework to quantify the reactivity of sulfonyl imidazole and triazole electrophiles across key biological nucleophiles together with matched plasma stability. Sulfonyl imidazoles display attenuated cysteine reactivity and markedly improved stability while retaining intrinsic tyrosine reactivity, whereas sulfonyl triazoles exhibit high electrophilicity and rapid degradation. These data reveal clear relationships between aryl electronics, leaving group ability, nucleophile selectivity, and in vivo ‐relevant stability. To demonstrate practical utility, we applied a SuFEx‐click transformation to convert the kinase‐directed probe XO44 into a sulfonyl imidazole analogue, yielding a stable SuDEx probe (JL‐51) that maintains the proteome‐labeling profile of the parent reagent. The corresponding sulfonyl triazole congener was rapidly hydrolyzed. This work provides a mechanistic foundation and practical strategy for designing next‐generation sulfonyl exchange covalent probes.

  • Open Access

    Covalent remodeling of CRBN creates a non-canonical neosubstrate interface with NTAQ1

    by Andres H. de la Peña, Justin T. Cruite, Jianwei Che, Mary E. Matyskiela, Philip P. Chamberlain, Eric S. Fischer, Lyn H. Jones

    Molecular glue degrader EM12-FS covalently modifies cereblon (CRBN) His353, enabling selective recruitment of the neosubstrate NTAQ1 to the CRL4 CRBN ubiquitin ligase. We determined the cryo-EM structure of the NTAQ1–EM12-FS–CRBN–DDB1 complex, revealing a non-canonical neosubstrate interface created by covalent remodeling of the CRBN sensor loop. Imidazylation repositions His353 to eliminate the steric clash that prevents NTAQ1 engagement by reversible IMiDs, and the engineered interface is stabilized by a distinctive T-shaped C-H/π interaction between sulfated His353 and NTAQ1 Phe126. Biochemical and mutational analyses define the determinants of ternary complex formation and ubiquitination. These findings show that site-specific synthetic modification of CRBN can reprogram induced-proximity pharmacology, expanding specificity beyond the G-loop degron and establishing a framework for covalent engineering of new degrader modalities.

  • Top Cited Papers

    Safety considerations for cereblon-recruiting targeted protein degraders

    by Helen Garside, Amy Aslamkhan, Danette L. Daniels, Kaushik Datta, Mikael Egebjerg, Renee R. Hukkanen, Lyn H. Jones, Natalie Ketter, Tejas S. Lahoti, Lise I. Loberg, et al.

    Targeted protein degraders (TPDs) that recruit the E3 ligase cereblon (CRBN) include two innovative drug classes: molecular glue degraders and proteolysis targeting chimeras. These TPDs have shown great promise in addressing difficult drug targets in oncologic and non-oncologic diseases; however, as well as inducing proteosomal degradation of their therapeutic target, they can also lead to degradation of unintended CRBN neosubstrates. This is a major safety consideration because many CRBN-recruiting TPDs are structurally related to thalidomide and other immunomodulatory imide drugs that are known to be teratogenic. The teratogenic effect of immunomodulatory imide drugs is due in part to their induction of CRBN-mediated neosubstrate degradation. Therefore, there is a need for a scientific consensus on rigorous, consistent and effective methods to assess the safety of CRBN-recruiting TPDs. Here, we provide an overview of the endogenous functions and substrates of CRBN as well as of the role of CRBN as the effector of immunomodulatory imide drugs, next-generation molecular glue degraders and proteolysis targeting chimeras. We discuss how degradation of unintended 'off-target' CRBN neosubstrates could potentially cause toxicity or safety liabilities in multiple organ systems as well as induce teratogenic effects. We outline key safety considerations for the development of CRBN-recruiting TPDs and suggest best practices for monitoring on-target versus off-target degradation.


  • Property-Based Optimization of Cereblon-Based Molecular Glue Degraders

    by Lyn H. Jones

    Molecular glue degraders that bind the E3 ligase adaptor cereblon are clinically precedented drugs used to treat cancer. Highly potent next-generation degraders are in development that target difficult-to-drug neosubstrates, such as transcription factors, for several different indications. This Microperspective covers the medicinal chemistry strategies being used to advance the property-based optimization of cereblon-based molecular glue degraders through consideration of their physicochemical characteristics.


  • Introduction to the themed collection on ‘Induced-Proximity Pharmacology’

    by Ingo V. Hartung, Lindsey I. James, Lyn H. Jones

    Ingo Hartung, Lindsey James and Lyn Jones introduce the RSC Medicinal Chemistry themed collection on ‘Induced-Proximity Pharmacology’.

  • Open Access

    Advances in sulfonyl exchange chemical biology: expanding druggable target space

    by Lyn H. Jones

    This Perspective assimilates developments in sulfonyl exchange chemical biology that have driven exciting advances in drug discovery and fundamental research over the last decade.


  • Structure-guided design of a truncated heterobivalent chemical probe degrader of IRE1α

    by Breanna L. Zerfas, Yingpeng Liu, Jianwei Che, Katherine A. Donovan, John M. Hatcher, Fidel Huerta, Rebecca J. Metivier, Radosław P. Nowak, Leah Ragosta, Tiffany Tsang, et al.

    The first degrader of an ER-resident protein (IRE1α) is described with properties more akin to a molecular glue than a traditional PROTAC, thus challenging the dogma of categorizing degrader modalities based on their physicochemical features.


  • Open Access

    Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency

    by Lara N. Gechijian, Giovanni Muncipinto, T. Justin Rettenmaier, Matthew T. Labenski, Victor Rusu, Lea Rosskamp, Leslie Conway, Daniel van Kalken, Liam Gross, Gianna Iantosca, et al.

    Mutations in creatine transporter SLC6A8 cause creatine transporter deficiency (CTD), which is responsible for 2% of all cases of X-linked intellectual disability. CTD has no current treatments and has a high unmet medical need. Inspired by the transformational therapeutic impact of small molecule "correctors" for the treatment of cystic fibrosis, which bind to mutated versions of the CFTR ion channel to promote its trafficking to the cell surface, we sought to identify small molecules that could stabilize SLC6A8 as a potential treatment for CTD. We leveraged a novel chemoproteomic technology for ligand discovery, reactive affinity probe interaction discovery, to identify small-molecule fragments with photoaffinity handles that bind to SLC6A8 in a cellular environment. We synthesized a library of irreversible covalent analogs of these molecules to characterize in functional assays, which revealed molecules that could promote the trafficking of mutant SLC6A8 variants to the cell surface. Further medicinal chemistry was able to identify reversible drug-like small molecules that both promoted trafficking of the transporter and also rescued creatine uptake. When profiled across the 27 most prevalent SLC6A8 missense variants, we found that 10-20% of patient mutations were amenable to correction by our molecules. These results were verified in an endogenous setting using the CRISPR knock-in of selected missense alleles. We established in vivo proof-of-mechanism for correctors in a novel CTD mouse model with the P544L patient-defined variant knocked in to the SLC6A8 locus, where treatment with our orally bioavailable and brain penetrant tool corrector increased brain creatine levels in heterozygous female mice, validating correctors as a potential therapeutic approach for CTD.